Yuri Maricich
Chief Tech/Sci/R&D Officer chez PEAR THERAPEUTICS, INC.
Fortune : - $ au 31/01/2024
Profil
Dr. Maricich leads the Clinical/Regulatory/Quality and Medical Affairs group at Pear Therapeutics as the Chief Medical Officer and Head of Development.
He leads and manages the development programs from Discovery/TPP stage, through Translational, Clinical Development, Regulatory submission and review as well as Medical Affairs.
In addition to overseeing subsequent pipeline programs across a broad-spectrum of disease areas (such as CNS/neuroscience, cardiovascular, and oncology), he led reSET (1st prescription digital therapeutic) and reSET-O (1st combination drug and software treatment) programs.
Dr. Maricich is a licensed, board-certified physician, investor, clinical developer and strategist.
He works to improve patient health and our healthcare system by investing in, advising, and providing leadership at innovative firms.
He has worked with and led successful teams and programs at Healthcare & Life Science/biotech (HLS) firms, including Corixa (acquired by GlaxoSmithKline), Xdynia (acquired by Cavion), Cavion (acquired by Jazz Pharmaceuticals), AWS, and Pear Therapeutics (1st FDA-cleared, clinically validated digital therapeutic to treat disease).
He founded a digital health firm while a med student that used AI and NLP to structure clinical data.
Dr. Maricich completed his education and training at Harvard University, the University of Washington, the University of Notre Dame, and the University of Virginia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/02/2023 | 94 333 ( 0,07% ) | - $ | 31/01/2024 |
Postes actifs de Yuri Maricich
| Sociétés | Poste | Début |
|---|---|---|
| PEAR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Pear Therapeutics (US), Inc.
 Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Pear Therapeutics (US), Inc. develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications. It offers eFormulation, pharmaceutical-software combination products. The firm combines digital therapies with supplements, medical foods and pharmaceuticals to create more effective treatment solutions. The company was founded in 2013 by Corey M. McCann, Stephen Kennedy Smith and William Greene and is headquartered in Boston. MA. | Chief Tech/Sci/R&D Officer | - |
Angelini Ventures SpA
 Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Consultant / Advisor | - |
Formation de Yuri Maricich
| University of Notre Dame | Undergraduate Degree |
| University of Washington | Doctorate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PEAR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Pear Therapeutics (US), Inc.
Pear Therapeutics (US), Inc. Packaged SoftwareTechnology Services Pear Therapeutics (US), Inc. develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications. It offers eFormulation, pharmaceutical-software combination products. The firm combines digital therapies with supplements, medical foods and pharmaceuticals to create more effective treatment solutions. The company was founded in 2013 by Corey M. McCann, Stephen Kennedy Smith and William Greene and is headquartered in Boston. MA. | Technology Services |
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Finance |
